Sarepta Theraps Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SAREPTA THERAPS INC
SAREPTA THERAPS INC has three approved drugs.
There are eleven US patents protecting SAREPTA THERAPS INC drugs.
Summary for Sarepta Theraps Inc
| US Patents: | 11 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
Drugs and US Patents for Sarepta Theraps Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | 9,506,058 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | 10,337,003 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | RX | Yes | Yes | RE48960 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | 10,364,431 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sarepta Theraps Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RE47751 | ⤷ Start Trial |
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | 10,781,451 | ⤷ Start Trial |
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | 9,416,361 | ⤷ Start Trial |
| Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | 10,533,174 | ⤷ Start Trial |
| Sarepta Theraps Inc | VYONDYS 53 | golodirsen | SOLUTION;INTRAVENOUS | 211970-001 | Dec 12, 2019 | 9,994,851 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Sarepta Theraps Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 275424 | ⤷ Start Trial |
| Australia | 2019203505 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2010050801 | ⤷ Start Trial |
| Hong Kong | 1216545 | ⤷ Start Trial |
| South Korea | 102239374 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
